Scalper1 News
Biogen Idec (BIIB) put up mixed results from a midstage trial of a much-anticipated new drug Thursday, seesawing the stock in early trading. The phase-two trial deployed a drug called anti-LINGO-1, a monoclonal antibody that acts against a protein called leucine rich repeat and Ig domain containing 1 (LINGO-1), against optic neuritis, a vision impairment that’s a common side effect of multiple scleroris due to the deteriorating myelin sheath Scalper1 News
Scalper1 News